Showing 877 results
-
Media Release /- Ilaris® (canakinumab) is the first and only FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF(1)- These three simultaneous approvals conducted under FDA Priority Review…
-
Media Release /New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
-
Media Release /Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril (1)These…
-
Media Release /This is the latest addition to the Alcon AIR OPTIX® portfolio of monthly replacement contact lenses which merges two unique technologiesSmartShield® Technology provides excellent deposit resistance…
-
Media Release /Together in HF social network is an innovative resource for information and support and a place to meet others with similar health experiencesNearly 6 million Americans have heart failure (HF), a…
-
Media Release /- New intraocular lens (IOL) combines two technologies that correct for presbyopia and corneal astigmatism simultaneously- This IOL is a new option for patients who desire good near, intermediate and…
-
Media Release /Sunovion assumes US commercialization rights for Utibron™ Neohaler®, Seebri™ Neohaler® and Arcapta® NeohalerNovartis will continue to manufacture these important medicines for SunovionIn line with…
-
Media Release /- 82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA)- ELIANA, the first global CAR T cell…
-
Media Release /Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cellsNovartis made an early commitment to the…
-
Media Release /New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
